Key Quantitative Figures

Standalone Financial Results (Quarter ended June 30, 2026):

  • Total Income: ₹1,064.11 crore
  • Revenue from operations: ₹832.66 crore
  • Other income: ₹231.45 crore
  • Total expenses: ₹1,018.06 crore
  • Purchase of stock-in-trade: ₹568.13 crore
  • Employee benefits expense: ₹122.94 crore
  • Finance costs: ₹57.42 crore
  • Profit before tax: ₹46.05 crore
  • Total tax expense: ₹11.48 crore
  • Profit for period: ₹34.57 crore
  • EPS (basic and diluted): ₹0.79
  • Paid-up equity share capital: ₹435.23 crore

Consolidated Financial Results (Quarter ended June 30, 2026):

  • Total Income: ₹19,435.02 crore
  • Revenue from operations: ₹19,404.95 crore
  • Other income: ₹30.07 crore
  • Total expenses: ₹18,763.82 crore
  • Purchase of stock-in-trade: ₹17,253.16 crore
  • Employee benefits expense: ₹694.16 crore
  • Finance costs: ₹205.72 crore
  • Profit before tax: ₹671.20 crore
  • Total tax expense: ₹150.69 crore
  • Profit for period: ₹520.51 crore
  • Profit attributable to owners: ₹381.62 crore
  • EPS (basic): ₹8.77
  • EPS (diluted): ₹8.76
  • Paid-up equity share capital: ₹435.23 crore

Dates of Action

  • Board meeting date: August 7, 2026
  • Meeting duration: 1:30 PM to 3:45 PM IST
  • Committee changes effective: August 25, 2026
  • Rajesh Shashikant Dalal tenure completion: August 24, 2026
  • Trading window to open: 48 hours after results disclosure

Parties Involved

Statutory Auditors: MS K A & Associates LLP (formerly MS KA & Associates)

Review Partner: Virendra Kanak (Membership No.: 110811)

Board Committee Reconstitution (effective August 25, 2026):

Audit Committee:

  • Sandhya Gadkari Sharma (Non-Executive Independent Director) - Chairperson
  • Sujesh Vasudevan (Non-Executive Independent Director) - Member
  • Prabhat Agrawal (Managing Director & CEO) - Member

Nomination and Remuneration Committee:

  • Sandhya Gadkari Sharma (Non-Executive Independent Director) - Chairperson
  • Sujesh Vasudevan (Non-Executive Independent Director) - Member
  • Arun Sadhanandham (Non-Executive Nominee Director) - Member

Stakeholders Relationship Committee:

  • Sujesh Vasudevan (Non-Executive Independent Director) - Chairperson
  • Arun Sadhanandham (Non-Executive Nominee Director) - Member
  • Prem Sethi (Whole Time Director & COO) - Member

Corporate Actions

Subsidiary Investments (OCD subscriptions during Q1 FY27):

  • Samshta Medi Solutions Private Limited: ₹3.33 crore (36,250 OCDs on May 20, 2026)
  • Sri Parshva Pharma Distributors Private Limited: ₹8.4 crore (38,000 OCDs on April 17, 2026)
  • S.S. Pharma Traders Private Limited: ₹55,000 (4,000 OCDs on May 22, 2026)
  • Avenues Pharma Distributors Private Limited: ₹5.6 crore (62,500 OCDs on April 18, 2026)

ESOP Activity:

  • Allotted 12,135 equity shares of ₹10 each at premium of ₹794 per share (aggregating ₹9.76 million) pursuant to employee stock option exercises
  • Granted 24,800 employee stock options under Entero Employee Stock Option Plan 2023

Financial Impact

Financial results have been reviewed by statutory auditors with unmodified opinion. All figures are unaudited but subject to limited review.

Additional Information

  • Company operates in single business segment: trading of pharmaceutical and surgical products
  • Figures for quarter ended March 31, 2026 are balancing figures between audited annual and limited reviewed nine-month figures
  • Results available on company website (www.enterohealthcare.com) and stock exchange websites